-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Tuesday's Intraday Session
Share
Listen to the news

Gainers

  • Polaryx Therapeutics (NASDAQ:PLYX) shares increased by 80.9% to $4.36 during Tuesday's regular session. The company's market cap stands at $114.0 million.
  • Baird Medical Investment (NASDAQ:BDMD) stock increased by 45.25% to $1.12. The company's market cap stands at $28.2 million.
  • Compass Pathways (NASDAQ:CMPS) stock increased by 42.42% to $8.28. The market value of their outstanding shares is at $543.5 million.
  • Masimo (NASDAQ:MASI) shares moved upwards by 34.4% to $174.93. The market value of their outstanding shares is at $7.0 billion.
  • Ensysce Biosciences (NASDAQ:ENSC) shares increased by 28.68% to $0.56. The company's market cap stands at $1.5 million.
  • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 21.75% to $1.31.

Losers

  • Liminatus Pharma (NASDAQ:LIMN) shares fell 33.9% to $0.25 during Tuesday's regular session. The company's market cap stands at $10.1 million.
  • Ocular Therapeutix (NASDAQ:OCUL) shares decreased by 24.84% to $6.67. The market value of their outstanding shares is at $1.9 billion.
  • Mainz Biomed (NASDAQ:MYNZ) shares fell 22.67% to $0.62. The company's market cap stands at $6.8 million.
  • Strata Skin Sciences (NASDAQ:SSKN) stock fell 18.25% to $0.28. The market value of their outstanding shares is at $2.0 million.
  • Quince Therapeutics (NASDAQ:QNCX) shares declined by 15.06% to $0.17. The company's market cap stands at $11.1 million.
  • Solid Biosciences (NASDAQ:SLDB) shares fell 14.22% to $5.31. The market value of their outstanding shares is at $482.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending